Results 201 to 210 of about 105,332 (309)

Nine‐Year Follow‐Up After M‐TEER for Secondary Mitral Regurgitation in a Patient With Cardiogenic Shock

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Transcatheter edge‐to‐edge repair (TEER) has become an established therapeutic option for patients with severe secondary mitral regurgitation (SMR). While randomized trials and registry data have reported outcomes up to 5 years, longer follow‐up data remain scarce.
Tobias Reithmayer   +9 more
wiley   +1 more source

A Survival Epidemiology Framework for Oral and Oropharyngeal Cancer

open access: yesCancer Nexus, EarlyView.
ABSTRACT Oral and oropharyngeal cancer remains a major global public health burden, but the literature addressing this disease is still organized predominantly around who develops it rather than around what determines life after diagnosis. That imbalance is consequential because diagnosis initiates a new scientific problem.
Raphael E. Cuomo
wiley   +1 more source

Perioperative Normobaric Hyperoxia Combined With Pulmonary Rehabilitation Intervention for Enhanced Short-Term Recovery in Lung Cancer Surgery. [PDF]

open access: yesThorac Cancer
Zhou M   +14 more
europepmc   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang   +7 more
wiley   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy